| Hector Ivan Sanchez, MD | |
|
1202 Medical Center Dr, Wilmington, NC 28401-7307 | |
| (910) 341-3300 | |
| (910) 251-2067 |
| Full Name | Hector Ivan Sanchez |
|---|---|
| Gender | Male |
| Speciality | Pulmonary Disease |
| Experience | 10 Years |
| Location | 1202 Medical Center Dr, Wilmington, North Carolina |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1124446513 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 2017-02173 (North Carolina) | Primary |
| 207RP1001X | Internal Medicine - Pulmonary Disease | 2017-02173 (North Carolina) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| New Hanover Regional Medical Center | Wilmington, NC | Hospital |
| J Arthur Dosher Memorial Hospital | Southport, NC | Hospital |
| Novant Health Brunswick Medical Center | Supply, NC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Wilmington Health Pllc | 6103722509 | 283 |
News Archive
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today updated the progress of its drug development programs and reported financial results for the three and six months ended June 30, 2010.
Regenicin, Inc., a development stage biotechnology company, announced today that it has completed an initial $3.25 million funding in conjunction with its acquisition of a worldwide exclusive license to know-how technology controlled by Lonza Walkersville ("Lonza Agreement").
Scientists reveal that a fault in the process that copies DNA during cell division can cause epigenetic changes that may be inherited for up-to five generations.
Discriminatory housing policies that restricted the sale or purchase of homes by race in certain neighborhoods across the U.S., called 'redlining,' which were established nearly a century ago and outlawed by the Fair Housing Act of 1968, were associated with higher rates of stroke in the same neighborhoods in 2017, according to preliminary research to be presented at the American Stroke Association's International Stroke Conference 2021.
› Verified 5 days ago
| Entity Name | Wilmington Health Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1881632339 PECOS PAC ID: 6103722509 Enrollment ID: O20031208000800 |
News Archive
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today updated the progress of its drug development programs and reported financial results for the three and six months ended June 30, 2010.
Regenicin, Inc., a development stage biotechnology company, announced today that it has completed an initial $3.25 million funding in conjunction with its acquisition of a worldwide exclusive license to know-how technology controlled by Lonza Walkersville ("Lonza Agreement").
Scientists reveal that a fault in the process that copies DNA during cell division can cause epigenetic changes that may be inherited for up-to five generations.
Discriminatory housing policies that restricted the sale or purchase of homes by race in certain neighborhoods across the U.S., called 'redlining,' which were established nearly a century ago and outlawed by the Fair Housing Act of 1968, were associated with higher rates of stroke in the same neighborhoods in 2017, according to preliminary research to be presented at the American Stroke Association's International Stroke Conference 2021.
› Verified 5 days ago
| Entity Name | Columbus Regional Health Network |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1508001009 PECOS PAC ID: 6608924931 Enrollment ID: O20090424000511 |
News Archive
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today updated the progress of its drug development programs and reported financial results for the three and six months ended June 30, 2010.
Regenicin, Inc., a development stage biotechnology company, announced today that it has completed an initial $3.25 million funding in conjunction with its acquisition of a worldwide exclusive license to know-how technology controlled by Lonza Walkersville ("Lonza Agreement").
Scientists reveal that a fault in the process that copies DNA during cell division can cause epigenetic changes that may be inherited for up-to five generations.
Discriminatory housing policies that restricted the sale or purchase of homes by race in certain neighborhoods across the U.S., called 'redlining,' which were established nearly a century ago and outlawed by the Fair Housing Act of 1968, were associated with higher rates of stroke in the same neighborhoods in 2017, according to preliminary research to be presented at the American Stroke Association's International Stroke Conference 2021.
› Verified 5 days ago
| Entity Name | Scotland Regional Health Network |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1972829562 PECOS PAC ID: 2365573185 Enrollment ID: O20100623000242 |
News Archive
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today updated the progress of its drug development programs and reported financial results for the three and six months ended June 30, 2010.
Regenicin, Inc., a development stage biotechnology company, announced today that it has completed an initial $3.25 million funding in conjunction with its acquisition of a worldwide exclusive license to know-how technology controlled by Lonza Walkersville ("Lonza Agreement").
Scientists reveal that a fault in the process that copies DNA during cell division can cause epigenetic changes that may be inherited for up-to five generations.
Discriminatory housing policies that restricted the sale or purchase of homes by race in certain neighborhoods across the U.S., called 'redlining,' which were established nearly a century ago and outlawed by the Fair Housing Act of 1968, were associated with higher rates of stroke in the same neighborhoods in 2017, according to preliminary research to be presented at the American Stroke Association's International Stroke Conference 2021.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Hector Ivan Sanchez, MD 1202 Medical Center Dr, Wilmington, NC 28401-7307 Ph: (910) 341-3300 | Hector Ivan Sanchez, MD 1202 Medical Center Dr, Wilmington, NC 28401-7307 Ph: (910) 341-3300 |
News Archive
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today updated the progress of its drug development programs and reported financial results for the three and six months ended June 30, 2010.
Regenicin, Inc., a development stage biotechnology company, announced today that it has completed an initial $3.25 million funding in conjunction with its acquisition of a worldwide exclusive license to know-how technology controlled by Lonza Walkersville ("Lonza Agreement").
Scientists reveal that a fault in the process that copies DNA during cell division can cause epigenetic changes that may be inherited for up-to five generations.
Discriminatory housing policies that restricted the sale or purchase of homes by race in certain neighborhoods across the U.S., called 'redlining,' which were established nearly a century ago and outlawed by the Fair Housing Act of 1968, were associated with higher rates of stroke in the same neighborhoods in 2017, according to preliminary research to be presented at the American Stroke Association's International Stroke Conference 2021.
› Verified 5 days ago
Dr. James Carden Mccabe, M.D. Internal Medicine Medicare: Medicare Enrolled Practice Location: 1302 Medical Center Dr, Wilmington, NC 28401 Phone: 910-343-9800 Fax: 910-343-9800 | |
Michael Mundy Ward, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2215 Canterwood Dr, Wilmington, NC 28401 Phone: 910-762-4600 Fax: 910-762-9483 | |
Latessa Spiers, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1960 S 16th St, Wilmington, NC 28401 Phone: 910-343-9991 | |
Dr. Kavita S Persaud, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 5919 Oleander Dr Ste 109, Wilmington, NC 28403 Phone: 910-799-5508 Fax: 910-202-0654 | |
Dr. Regina Marie Jensen, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 4536 Technology Dr, Ste 3, Wilmington, NC 28405 Phone: 910-343-8411 Fax: 910-343-8414 | |
Mary Kathryn Rudyk, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1709 S 16th St Ste A, Wilmington, NC 28401 Phone: 910-452-8633 Fax: 910-452-8569 | |
Gregory Roberts, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1202 Medical Center Dr, Wilmington, NC 28401 Phone: 910-341-3300 Fax: 910-341-7946 |